SunWay Biotech Co., LTD.
SunWay Biotech Co., LTD. focuses on professional research and development, and technical material manufacturing and processing business. The company offers red yeast rice and lactic acid bacteria products, as well as other health supplements; and wholesale and manufacturing of pharmaceutical products. The company also researches, designs, and manufactures Monascus purpureus NTU 568; Lactobacillus… Read more
SunWay Biotech Co., LTD. (1271) - Net Assets
Latest net assets as of June 2025: NT$3.23 Billion TWD
Based on the latest financial reports, SunWay Biotech Co., LTD. (1271) has net assets worth NT$3.23 Billion TWD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$4.17 Billion) and total liabilities (NT$939.36 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$3.23 Billion |
| % of Total Assets | 77.45% |
| Annual Growth Rate | 63.55% |
| 5-Year Change | 602.79% |
| 10-Year Change | N/A |
| Growth Volatility | 402.1 |
SunWay Biotech Co., LTD. - Net Assets Trend (2019–2024)
This chart illustrates how SunWay Biotech Co., LTD.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for SunWay Biotech Co., LTD. (2019–2024)
The table below shows the annual net assets of SunWay Biotech Co., LTD. from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$3.27 Billion | +2.03% |
| 2023-12-31 | NT$3.20 Billion | +1010.90% |
| 2022-12-31 | NT$288.09 Million | -47.34% |
| 2021-12-31 | NT$547.05 Million | +17.74% |
| 2020-12-31 | NT$464.62 Million | +66.65% |
| 2019-12-31 | NT$278.80 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to SunWay Biotech Co., LTD.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 22733500000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$121.08 Million | 3.71% |
| Common Stock | NT$603.89 Million | 18.51% |
| Other Components | NT$2.54 Billion | 77.78% |
| Total Equity | NT$3.26 Billion | 100.00% |
SunWay Biotech Co., LTD. Competitors by Market Cap
The table below lists competitors of SunWay Biotech Co., LTD. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Southern Rubber Industry JSC
VN:CSM
|
$45.04 Million |
|
Coxon Precise Industrial Co Ltd
TW:3607
|
$45.04 Million |
|
Barem Ambalaj Sanayi ve Ticaret a.s.
IS:BARMA
|
$45.05 Million |
|
Right Way Industrial Co Ltd
TW:1506
|
$45.05 Million |
|
Accuray Incorporated
NASDAQ:ARAY
|
$45.01 Million |
|
SYN-Tech Chem & Pharm Co Ltd
TWO:1777
|
$45.00 Million |
|
DURECT CORP. DL-001
F:DC8A
|
$44.99 Million |
|
IF Bancorp Inc
NASDAQ:IROQ
|
$44.99 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SunWay Biotech Co., LTD.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 3,197,462,000 to 3,262,703,000, a change of 65,241,000 (2.0%).
- Net income of 118,572,000 contributed positively to equity growth.
- Dividend payments of 59,389,000 reduced retained earnings.
- Other comprehensive income decreased equity by 4,215,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$118.57 Million | +3.63% |
| Dividends Paid | NT$59.39 Million | -1.82% |
| Other Comprehensive Income | NT$-4.21 Million | -0.13% |
| Other Changes | NT$10.27 Million | +0.31% |
| Total Change | NT$- | 2.04% |
Book Value vs Market Value Analysis
This analysis compares SunWay Biotech Co., LTD.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.96x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 6.16x to 0.96x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | NT$8.40 | NT$51.80 | x |
| 2020-12-31 | NT$14.47 | NT$51.80 | x |
| 2021-12-31 | NT$15.83 | NT$51.80 | x |
| 2022-12-31 | NT$14.25 | NT$51.80 | x |
| 2023-12-31 | NT$104.34 | NT$51.80 | x |
| 2024-12-31 | NT$53.98 | NT$51.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently SunWay Biotech Co., LTD. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.63%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 12.22%
- • Asset Turnover: 0.26x
- • Equity Multiplier: 1.16x
- Recent ROE (3.63%) is below the historical average (14.58%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 13.71% | 22.21% | 0.54x | 1.14x | NT$10.36 Million |
| 2020 | 27.20% | 39.98% | 0.62x | 1.11x | NT$79.49 Million |
| 2021 | 31.04% | 44.36% | 0.63x | 1.12x | NT$114.39 Million |
| 2022 | 10.43% | 7.06% | 0.89x | 1.66x | NT$1.23 Million |
| 2023 | 1.44% | 8.07% | 0.16x | 1.14x | NT$-273.66 Million |
| 2024 | 3.63% | 12.22% | 0.26x | 1.16x | NT$-207.70 Million |
Industry Comparison
This section compares SunWay Biotech Co., LTD.'s net assets metrics with peer companies in the Packaged Foods industry.
Industry Context
- Industry: Packaged Foods
- Average net assets among peers: $17,559,023,800
- Average return on equity (ROE) among peers: 8.12%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SunWay Biotech Co., LTD. (1271) | NT$3.23 Billion | 13.71% | 0.29x | $45.04 Million |
| Wei Chuan Foods Corp (1201) | $5.55 Billion | 12.34% | 1.69x | $125.16 Million |
| Ve Wong Corp (1203) | $6.25 Billion | 7.16% | 0.53x | $76.18 Million |
| Great Wall Enterprise Co Ltd (1210) | $7.57 Billion | 10.72% | 1.28x | $893.11 Million |
| Charoen Pokphand Enterprise Taiwan Co Ltd (1215) | $5.36 Billion | 14.61% | 0.75x | $839.68 Million |
| Uni-President Enterprises Corp (1216) | $130.79 Billion | 9.49% | 1.59x | $10.01 Billion |
| AGV Products Corp (1217) | $6.27 Billion | 0.76% | 1.01x | $116.99 Million |
| Taisun Enterprise Co Ltd (1218) | $3.67 Billion | 6.42% | 1.09x | $108.34 Million |
| Fwusow Industry Co Ltd (1219) | $3.96 Billion | 5.13% | 1.26x | $99.99 Million |
| Tai Roun Products Co Ltd (1220) | $2.53 Billion | 5.26% | 0.26x | $37.61 Million |
| Formosa Oilseed Processing Co Ltd (1225) | $3.65 Billion | 9.29% | 1.12x | $49.69 Million |